Navigation Links
Results of the Annual General Meeting Held on September 24, 2008
Date:9/24/2008

DUBLIN, Ireland, September 24 /PRNewswire-FirstCall/ -- Shire Limited (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, announces that at its Annual General Meeting today, all resolutions contained in the notice of meeting were duly passed and the results of the poll are as follows:

For* Against Withheld**

1. To elect Mr Matthew 301,376,910 4,696,170 25,441,808

Emmens as a Director

of the Company

2. To elect Mr Angus 331,225,599 138,229 151,060

Russell as a

Director of the

Company

3. To elect Mr Graham 331,234,635 127,173 153,080

Hetherington as a

Director of the

Company

4. To elect Dr Barry 328,858,454 2,501,778 154,656

Price as a Director

of the Company

5. To elect Mr David 330,945,634 412,470 156,784

Kappler as a

Director of the

Company

6. To elect Dr Jeffrey 331,221,109 138,828 154,951

Leiden as a Director

of the Company

7. To elect Mr Patrick 330,949,493 412,089 153,306

Langlois as a

Director of the

Company

8. To elect Ms Kate 331,014,606 346,949 153,333

Nealon as a Director

of the Company

9. To elect Mr David 327,884,774 2,101,928 1,528,186

Mott as a Director

of the Company

10. To elect Dr Michael 331,232,603 126,815 155,470

Rosenblatt as a

Director of the

Company

11. To re-appoint 327,634,578 1,301,388 2,578,922

Deloitte & Touche

LLP as Auditors of

the Company

12. To authorise the 331,225,599 1,470,679 159,584

Audit, Compliance

and Risk Committee

to determine the

remuneration of the

Auditors

13. To authorise the 328,104,104 3,189,130 221,654

allotment of shares

14. To authorise the 329,760,418 1,575,955 178,515

disapplication of

pre-emption rights

15. To authorise market 330,598,450 729,745 186,693

purchases

16. To change the name 331,323,817 31,609 159,462

of the Company to

Shire plc

Notes to Editors

Shire Limited Shire's strategic goal is to become the leading specialty biopharmaceutical company that focuses on meeting the needs of the specialist physician. Shire focuses its business on attention deficit hyperactivity disorder (ADHD), human genetic therapies (HGT) and gastrointestinal (GI) diseases as well as opportunities in other therapeutic areas to the extent they arise through acquisitions. Shire's in-licensing, merger and acquisition efforts are focused on products in specialist markets with strong intellectual property protection and global rights. Shire believes that a carefully selected and balanced portfolio of products with strategically aligned and relatively small-scale sales forces will deliver strong results.

For further information on Shire, please visit the Company's website: http://www.shire.com.

For further information please contact:

Investor Relations Clea Rosenfeld (Rest of the World) +44-1256-894-160

Eric Rojas (North America) +1-484-595-8252

Media Jessica Mann (Rest of the World) +44-1256-894-280

Matthew Cabrey (North America) +1-484-595-8248

Jessica Cotrone (North America) +1-617-613-4640


'/>"/>
SOURCE Shire Ltd
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
2. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
3. Healthcare Technologies Reports Loss for 2007 Second Quarter & Six Months Results
4. CNS Response Announces Fiscal Third Quarter 2007 Results
5. Skystar Bio-Pharmaceutical Announces Second Quarter 2007 Results
6. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
7. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
8. Carrington Reports Second Quarter 2007 Results
9. Avitar Reports Third Quarter Financial Results for Fiscal 2007
10. Response Genetics Reports Second Quarter 2007 Financial Results
11. Martek to Announce Third Quarter 2007 Results on September 5, 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/22/2016)... ... June 22, 2016 , ... Quantitative ... business incubator and current participant in the Phase 1 Ventures program, is leveraging ... , Quantitative Radiology Solutions helps physicians make better treatment decisions by quantifying ...
(Date:6/22/2016)... (PRWEB) , ... June 21, 2016 , ... New light-based ... cutting into the tissue — promise to enable both compact, wearable devices for point-of-care ... even deeper under the skin. , Recent work and visionary future directions are detailed ...
(Date:6/22/2016)... SAN DIEGO , June 22, 2016 /PRNewswire/ ... that has developed a testing platform designed specifically ... the formation of their scientific advisory board (SAB). ... of directors, the SAB is chartered to advise ... infectious disease assay platform. Led by Dr. ...
(Date:6/22/2016)... June 22, 2016 On Tuesday, June ... 4,843.76, up 0.14%; the Dow Jones Industrial Average advanced 0.14% ... 2,088.90, up 0.27%. The gains were broad based as five ... has initiated coverage on the following equities: Minerva Neurosciences Inc. ... PTLA ), Trevena Inc. (NASDAQ: TRVN ), ...
Breaking Biology Technology:
(Date:4/28/2016)... First quarter 2016:   , ... the first quarter of 2015 The gross margin was ... 18.8) and the operating margin was 40% (-13) Earnings ... flow from operations was SEK 249.9 M (21.2) , ... SEK 7,000-8,500 M. The operating margin for 2016 is ...
(Date:4/19/2016)... 2016 The new GEZE SecuLogic ... web-based "all-in-one" system solution for all door components. It ... the door interface with integration authorization management system, and ... The minimal dimensions of the access control and the ... installations offer considerable freedom of design with regard to ...
(Date:4/14/2016)... BioCatch ™, the global ... the appointment of Eyal Goldwerger as CEO. ... Goldwerger,s leadership appointment comes at a time of significant ... of its platform at several of the world,s largest ... unique cognitive and physiological factors, is a winner of ...
Breaking Biology News(10 mins):